Clinical studies have indicated that the NV (nanovesicle) concentration in blood samples is a potential indicator of clinical status and can be used to follow the development of the disease. For 32 months, we monitored the effect of imatinib treatment on NV concentrations in blood samples from 12 patients with GIST (gastrointestinal stromal tumour). The NV concentration before the treatment increased with respect to control by a factor of 3.5 on average (range 2.6–9.2). The first week after initiation of the treatment, the NV concentration increased considerably, by a factor of 13 on average (range 5.9–21.2), whereas on average, after 1 month, it decreased to the level of the control and remained at that level for at least 1.5 years. Recent assessment (after 2.5 years) showed a somewhat increased NV concentration, by a factor of 2 on average (range 0.7–3.9). Low NV concentrations in blood samples during the treatment reflect a favourable effect of imatinib in these patients and no remission of the disease was hitherto observed.
Skip Nav Destination
Article navigation
February 2013
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
January 29 2013
A 32-month follow-up study of nanovesicle concentrations in blood from 12 patients with gastrointestinal stromal tumour treated with imatinib
Eva Ogorevc;
Eva Ogorevc
*Laboratory of Biophysics, Faculty of Electrical Engineering, University of Ljubljana, Tržaška 25, SI-1000 Ljubljana, Slovenia
Search for other works by this author on:
Roman Štukelj;
Roman Štukelj
†Biomedical Research Group, Faculty of Health Sciences, University of Ljubljana, Zdravstvena 5, SI-1000 Ljubljana, Slovenia
Search for other works by this author on:
Apolonija Bedina-Zavec;
Apolonija Bedina-Zavec
‡Laboratory of Biosynthesis and Biotransformation, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia
Search for other works by this author on:
Vid Šuštar;
Vid Šuštar
§Laboratory of Clinical Biophysics, Chair of Orthopaedic Surgery, Faculty of Medicine, University of Ljubljana, Lipičeva 2, SI-1000, Ljubljana, Slovenia
Search for other works by this author on:
Metka Šimundić;
Metka Šimundić
†Biomedical Research Group, Faculty of Health Sciences, University of Ljubljana, Zdravstvena 5, SI-1000 Ljubljana, Slovenia
Search for other works by this author on:
Veronika Kralj-Iglič;
Veronika Kralj-Iglič
1
†Biomedical Research Group, Faculty of Health Sciences, University of Ljubljana, Zdravstvena 5, SI-1000 Ljubljana, Slovenia
1To whom correspondence should be addressed (email[email protected]).
Search for other works by this author on:
Rado Janša
Rado Janša
∥Clinical Department of Gastroenterology, Ljubljana University Medical Centre, Zaloška cesta 7, SI-1000 Ljubljana, Slovenia
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
September 18 2012
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2013 Biochemical Society
2013
Biochem Soc Trans (2013) 41 (1): 303–308.
Article history
Received:
September 18 2012
Citation
Eva Ogorevc, Roman Štukelj, Apolonija Bedina-Zavec, Vid Šuštar, Metka Šimundić, Veronika Kralj-Iglič, Rado Janša; A 32-month follow-up study of nanovesicle concentrations in blood from 12 patients with gastrointestinal stromal tumour treated with imatinib. Biochem Soc Trans 1 February 2013; 41 (1): 303–308. doi: https://doi.org/10.1042/BST20120247
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Get Email Alerts
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |